Acceleron Pharma is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics to treat diseases. Co.'s research focuses on natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining Co.'s discovery and development capabilities, including its proprietary knowledge of the TGF-beta superfamily, and its internal protein engineering and manufacturing capabilities, Co. generates therapeutic candidates, all of which encompass potential mechanisms of action. Co. has focused and prioritized its research and development activities within pulmonary and hematology. The XLRN stock yearly return is shown above.
The yearly return on the XLRN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XLRN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|